Claude H. Nash, PhD
Chief Executive Officer and Chairman

Paul J. Leibowitz, PhD
Chief Technology Officer and Director

Julian M.E. Lee, MA (Cantab), ACA
Chief Financial Officer and Director

Sandra Panem, PhD
Director

Robert J. Powell, Ph.D., MBA
Vice President, University Liaison

Eric R. Leibowitz, Esq.
In-House Counsel



Francis J. Bullock, PhD

Gerald Malone, MA, LLB

Seth A. Rudnick, MD

Natalie S. Rudolph, PhD



Bingham McCutchen LLP
US corporate counsel

Fasken Martineau LLP
UK corporate counsel

Seth Rudnick, M.D. is a General Partner of Canaan Partners, a venture capital firm he joined in 1998 focusing on health care investments. Dr. Rudnick’s background in the health care industry includes comprehensive experience in research, development, clinical trials analysis and biotechnology, as well as founding and growing start-up companies in the industry.

Prior to joining Canaan, Dr. Rudnick had served as CEO and Chairman at CytoTherapeutics (CTII). Before that, he helped found and served as head of R&D for Ortho Biotech, a division of Johnson & Johnson. In that role, he led development efforts for a portfolio of projects whose worldwide revenues now exceed $1-billion in annual sales. Dr. Rudnick began his industrial career at Schering-Plough where he ran clinical trials for the alpha interferon project, and later transferred to Biogen to run that company's pharmaceutical development efforts.

His academic career began when he served on the medical and public health faculty at the University of North Carolina School of Medicine at Chapel Hill. Dr. Rudnick is a Clinical Professor of Medicine at University of North Carolina, Chapel Hill where he teaches and advises the faculty on biotechnology issues

Dr. Rudnick advises Bloodstone with respect to scientific matters.